RT Journal Article SR Electronic T1 Survival outcomes of primary cutaneous T-cell lymphoma in HIV-infected patients: a national population-based study JF Journal of Investigative Medicine JO J Investig Med FD BMJ Publishing Group Ltd SP 762 OP 767 DO 10.1136/jim-2017-000636 VO 66 IS 4 A1 Jianhong Wang A1 Rong Liang A1 Caixia Hao A1 Xiangxiang Liu A1 Na Zhang A1 Xiaohui Duan A1 Hongjuan Dong A1 Baoxia Dong A1 Hongtao Gu A1 Guangxun Gao A1 Tao Zhang A1 Qingxian Bai A1 Xiequn Chen YR 2018 UL http://hw-f5-jim.highwire.org/content/66/4/762.abstract AB This study aimed to investigate clinical characteristics and survival outcomes of primary cutaneous T-cell lymphoma (CTCL) in HIV-infected and non-HIV-infected patients. All data were from the Surveillance, Epidemiology, and End Results program, 1973–2013, of the U.S. National Cancer Institute. Data of 318 HIV-infected patients and 1272 non-HIV-infected patients with primary CTCL were analyzed. Endpoints were overall survival and cancer-specific mortality. Independent variables included demographics, pre-existing malignancy, treatments, and environmental factors. Among 8823 patients with CTCL, 318 (3.60 per cent) were HIV-infected and 8505 (96.40 per cent) were not. 318 HIV-infected patients and 1272 non-HIV-infected patients selected by matching diagnosis dates were analyzed, including 941 (59.2 per cent) males and 649 (40.8 per cent) females with mean age 58.8 years. HIV-infected patients with CTCL had higher survival and significantly lower risk of overall mortality than non-HIV-infected patients (adjusted HR 0.37, 95 per cent CI 0.24 to 0.59, P<0.001). Non-HIV-infected, age and black race were significant risk factors for overall mortality. Age and race are independent risk factors for overall mortality in primary CTCL individuals, and HIV-infected status is an independent protective factor, suggesting that advanced antiretroviral therapy restores immunity and prolongs survival in HIV-infected patients with CTCL.